Discovery of C-3 isoxazole substituted thiochromone S,S-dioxide derivatives as potent and selective inhibitors for monoamine oxidase B (MAO-B).


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Jan 2024
Historique:
received: 17 09 2023
revised: 12 11 2023
accepted: 13 11 2023
medline: 4 12 2023
pubmed: 23 11 2023
entrez: 22 11 2023
Statut: ppublish

Résumé

Developing new scaffolds for highly potent and selective inhibitors of human Monoamine Oxidase B (hMAO-B) is a crucial objective in enhancing the efficacy and safety in the clinical treatment of neurodegenerative diseases. In this study, we have identified a series of C-3 isoxazole-substituted thiochromone S,S-dioxide derivatives that exhibit strong inhibitory activity against hMAO-B. The strategy of oxidizing thiochromone to thiochromone S,S-dioxide solves the key defect of extreme insolubility observed for thiochromone analogues. In addition, the sulfone group contributes extra hydrogen(H)-bonding interactions with Tyr435, which significantly increases the activity of thiochromone S,S-dioxide derivatives against hMAO-B. Furthermore, the presence of isoxazole group provides potential H-bonding interaction and electrostatic interaction with the residue of Tyr326, while the rigid aryl ring introduces a potential steric conflict with Phe208 of hMAO-A to improve both potency and selectivity. In our investigations, several compounds (9c, 10c, 10e, 10g, 10l and 10m) demonstrate remarkable single-digit nanomolar potency. These compounds exhibit favorable cytotoxicity profiles in both differentiated SH-SY5Y and HVSMC cells, without apparent cardiotoxic effects. Moreover, compounds 10e and 10h do not lead to an increase in ROS levels in differentiated SH-SY5Y cells, further demonstrating their potential as safe and effective hMAO-B inhibitors. These findings indicate that the C-3 isoxazole substituted thiochromone S,S-dioxide analogues are potential leading compounds for the development of selective inhibitors with high potency.

Identifiants

pubmed: 37992521
pii: S0223-5234(23)00923-6
doi: 10.1016/j.ejmech.2023.115956
pii:
doi:

Substances chimiques

Monoamine Oxidase EC 1.4.3.4
Monoamine Oxidase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115956

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Pengbing Mi (P)

Department of Pharmacy, Hengyang Medicinal School, University of South China, Hengyang, Hunan 421001, China; Key Lab of Protein Structure and Function of Universities in Hunan Province, University of South China, Hengyang, Hunan 421001, China. Electronic address: geyynb@foxmail.com.

Yan Tan (Y)

Department of Pharmacy, Hengyang Medicinal School, University of South China, Hengyang, Hunan 421001, China.

Shiying Ye (S)

Department of Pharmacy, Hengyang Medicinal School, University of South China, Hengyang, Hunan 421001, China.

Jia-Jia Lang (JJ)

School of Chemistry and Chemical Engineering, University of South China, Hengyang, Hunan 421001, China; Key Lab of Protein Structure and Function of Universities in Hunan Province, University of South China, Hengyang, Hunan 421001, China.

You Lv (Y)

College of Bioresources Chemical and Materials Engineering, Shaanxi University of Science & Technology, Xi'an, Shaanxi 710021, China; Xi'an Amazinggene Co., Ltd, Xi'an, Shaanxi 710026, China.

Jinhuan Jiang (J)

Department of Pharmacy, Hengyang Medicinal School, University of South China, Hengyang, Hunan 421001, China.

Limei Chen (L)

Department of Pharmacy, Hengyang Medicinal School, University of South China, Hengyang, Hunan 421001, China.

Jianxiong Luo (J)

Department of Pharmacy, Hengyang Medicinal School, University of South China, Hengyang, Hunan 421001, China.

Yuqing Lin (Y)

Department of Pharmacy, Hengyang Medicinal School, University of South China, Hengyang, Hunan 421001, China.

Zhonghua Yuan (Z)

Department of Pharmacy, Hengyang Medicinal School, University of South China, Hengyang, Hunan 421001, China. Electronic address: yzh5555@163.com.

Xing Zheng (X)

Department of Pharmacy, Hengyang Medicinal School, University of South China, Hengyang, Hunan 421001, China; Department of Pharmacy, Hunan Vocational College of Science and Technology, Changsha, Hunan 410004, China. Electronic address: zhengxing9166@sohu.com.

Ying-Wu Lin (YW)

School of Chemistry and Chemical Engineering, University of South China, Hengyang, Hunan 421001, China; Key Lab of Protein Structure and Function of Universities in Hunan Province, University of South China, Hengyang, Hunan 421001, China. Electronic address: ywlin@usc.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH